• Explore /
  • Poster
  • / A phase 2 randomized open-label study of oral darolutamide monotherapy vs. androgen deprivation therapy in men with hormone-naive prostate cancer (EORTC-GUCG 1532).

A phase 2 randomized open-label study of oral darolutamide monotherapy vs. androgen deprivation therapy in men with hormone-naive prostate cancer (EORTC-GUCG 1532).

Abstract Poster

Authors

Bertrand Tombal

Bertrand F. Tombal

Division of Urology, IREC, Cliniques Universitaires Saint Luc, UCLouvain, Brussels, Belgium

Bertrand F. Tombal , Francisco Gomez-Veiga , Alvaro Gomez-Ferrer , Fernando López-Campos , Piet Ost , Thierry Andre Roumeguere , Bernardo Herrera-Imbroda , Lionel A. D'Hondt , Magali Quivrin , Paolo Gontero , Salvador Villà , Hussein Mustafa Khaled , Beatrice Fournier , Joanna Krzystyniak , Yassin Pretzenbacher , Hazal Erkol , Yohann Loriot

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02972060

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 160)

DOI

10.1200/JCO.2023.41.6_suppl.160

Abstract #

160

Poster Bd #

E20

Abstract Disclosures

Similar Posters

First Author: Bertrand F. Tombal

First Author: Andrew Leonard Laccetti

First Author: Fernando C. Maluf

First Author: Bertrand F. Tombal